Clinical Study of VG161 in Advanced Intrahepatic Cholangiocarcinoma

This study tests a cancer-killing virus called VG161 (an oncolytic herpes virus engineered to activate the immune system) injected directly into tumors in people with advanced intrahepatic cholangiocarcinoma (bile duct cancer inside the liver) that has stopped responding to standard first-line treatment. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed advanced bile duct cancer inside the liver - Your cancer has progressed on or you could not tolerate at least one prior standard treatment - You have a measurable tumor that can be injected under ultrasound or CT guidance (longest diameter > 1.5 cm) - You have tested positive for herpes simplex virus type 1 (HSV-1) antibodies - Your ECOG performance status is 0 or 1 - Your organ function is adequate **You may NOT be eligible if...** - You have received anti-tumor treatment within the past 4 weeks - You have cancer spread to the brain or spine - You are in an active herpes outbreak (cold sores, genital herpes, etc.) - You have HIV, active hepatitis B or C - You have a history of serious heart disease in the past 6 months - You have active autoimmune disease that requires systemic treatment - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.